Aktis Oncology, Inc. (AKTS) vs Rigel Pharmaceuticals, Inc. (RIGL)
- Aktis Oncology, Inc. AKTS 15.06 −5.93%
- Rigel Pharmaceuticals, Inc. RIGL 45.97 −2.71%
Aktis Oncology, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Rigel Pharmaceuticals, Inc. are of similar size ($890.5M and $882.6M). Aktis Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. has the higher net margin (116.3% vs −782.0%) and the higher return on invested capital (16.5% vs 0.00%). Across the 15 metrics below, Rigel Pharmaceuticals, Inc. leads on 12 and Aktis Oncology, Inc. on 3.
Valuation
Profitability
| Metric | AKTS | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 91.39% | 65.16% |
| Operating margin | (939.13%) | 31.45% | 0.00% |
| Net margin | (781.95%) | 116.30% | 0.00% |
| Free cash flow margin | (1,442.91%) | 3.19% | 0.00% |
| Return on equity | (34.45%) | 126.90% | (56.36%) |
| Return on assets | (22.22%) | 88.46% | (48.04%) |
| Return on invested capital | 0.00% | 16.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack